01 June 2026
01 June 2026
The approval relies on positive data from the POTOMAC Phase III trial.
The trial will assess if direct outreach by healthcare providers increases cascade genetic testing among first-degree relatives.
The trial is expected to recruit around 100 healthy overweight or obese volunteers.
Procept BioRobotics anticipates sharing the primary endpoint results from WATER IV in 2027.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
